Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 28;13:968729. doi: 10.3389/fimmu.2022.968729

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Zhou, Huang, Wong, Hu, Zhu, Li and Zhou

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The subgroup analysis between ATB use and different immune checkpoint inhibitors of cancer patients treated with ICIs. (A) The association between ATB use and OS in cancer patients treated with the combination of PD-1 inhibitor and PD-L1 inhibitor. (B) The association between ATB use and OS in cancer patients treated with PD-1 inhibitor. (C) The association between ATB use and OS in cancer patients treated with PD-L1 inhibitor. (D) The association between ATB use and PFS in cancer patients treated with the combination of PD-1 inhibitor and PD-L1 inhibitor. (E) The association between ATB use and PFS in cancer patients treated with PD-1 inhibitor.